TABLE 3.
Antimicrobial susceptibility among 208 Salmonella enterica isolates from humans with infections in Henan Province, China, during 2006 and 2007 and 27 serovar Typhimurium isolates from 1987 to 1993
| S. enterica serovar or serotype (yr of isolation) | No. of isolates | No. of isolates resistant to indicated agent at the indicated breakpoint in mg/liter (% resistance)a
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CIP
|
NAL, ≥32 | STR, ≥32 | SMX, ≥512 | TET, ≥16 | TMP, ≥16 | SPE, ≥128 | AMP, ≥32 | CHL, ≥32 | GEN, ≥8 | NEO, ≥16 | FFN, ≥32 | APR, ≥32 | POD, ≥4 | XNL, ≥8 | |||
| ≥4 | 0.125-2 | ||||||||||||||||
| Typhimurium (2006-2007) | 56 | 41 (73) | 13 (23) | 53 (95) | 51 (91) | 53 (95) | 50 (89) | 54 (96) | 53 (95) | 53 (95) | 47 (84) | 53 (95) | 12 (21) | 8 (14) | 6 (11) | 5 (9) | 5 (9) |
| Typhimurium (1987-1993) | 27 | 2 (7) | 18 (67) | 20 (74) | 25 (93) | 25 (93) | 24 (89) | 25 (93) | 25 (93) | 25 (93) | 25 (93) | 25 (93) | 9 (33) | 3 (11) | 0 | 5 (19) | 0 |
| Enteritidis | 35 | 2 (6) | 32 (91) | 34 (97) | 4 (11) | 4 (11) | 5 (1) | 2 (6) | 2 (6) | 4 (11) | 3 (9) | 3 (9) | 1 (3) | 1 (3) | 1 (3) | 0 | 0 |
| Derby | 20 | 0 | 1 (5) | 1 (5) | 5 (25) | 6 (30) | 9 (45) | 2 (10) | 5 (25) | 0 | 7 (35) | 0 | 0 | 2 (10) | 0 | 0 | 0 |
| Indiana | 12 | 8 (67) | 4 (33) | 12 (100) | 9 (75) | 12 (100) | 12 (100) | 11 (92) | 11 (92) | 12 (100) | 12 (100) | 10 (83) | 8 (67) | 8 (67) | 8 (67) | 0 | 0 |
| Litchfield | 12 | 0 | 0 | 0 | 7 (59) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Corvallis | 3 | 0 | 0 | 0 | 3 (100) | 3 (100) | 3 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infantis | 3 | 0 | 1 (33) | 1 (33) | 0 | 1 (33) | 0 | 1 (33) | 0 | 1 (33) | 1 (33) | 0 | 0 | 1 (33) | 0 | 0 | 0 |
| 6,7:e,h:− | 3 | 0 | 3 (100) | 3 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bovismorbificans | 3 | 0 | 3 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kentucky | 2 | 0 | 2 (100) | 1 (50) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Choleraesuis | 1 | 0 | 1 (100) | 1 (100) | 0 | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 | 0 | 0 | 0 |
| Singapore | 1 | 0 | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Somone | 1 | 0 | 0 | 0 | 1 (100) | 1 (100) | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IV | 1 | 0 | 0 | 0 | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Othersb | 55 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total (2006-2007) | 208 (27) | 51 (25) | 61 (29) | 107 (51) | 82 (39) | 82 (39) | 82 (39) | 72 (35) | 72 (35) | 71 (34) | 71 (34) | 67 (32) | 22 (11) | 20 (10) | 15 (7) | 5 (2) | 5 (2) |
a
All isolates were susceptible to colistin and amoxicillin plus clavulanate. CIP, ciprofloxacin; NAL, nalidixic acid; STR, streptomycin; SMX, sulfamethoxazole; TET, tetracycline; TMP, trimethoprim; SPE, spectinomycin; AMP, ampicillin; CHL, chloramphenicol; GEN, gentamicin; NEO, neomycin; FFN, florfenicol; APR, apramycin; POD, cefpodoxime; XNL, ceftiofur.
b
Isolates belonging to the remaining 18 serovars were susceptible to all the antimicrobials tested.